Protagonist Therapeutics, Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+6.45%
vs ±11.8% implied · ×0.55
shaded = implied · ▲▼ = realized
Protagonist Therapeutics has 0 disclosed suppliers and 2 disclosed customers in SEC filings.
Protagonist Therapeutics, Inc
144.17
SentenceWe discovered rusfertide, advanced it into Phase 3 development, and in early 2024 entered into a co-development and co-commercialization arrangement with Takeda Pharmaceuticals, Inc. ("Takeda") under a license and collaboration agreement entered into in January 2024.
—
Linked news
Expected move
Inputs8Q avg ±3.1%·×1.81·rich
straddle ±7.7%
spot 144.85exp Nov 20ATM strike 145ATM straddle 13.20IV 48%